Schwarz files Parkinson’s patch
This article was originally published in Pharmaceutical Approvals Monthly
Schwarz' Sept. 29 submission of Neupro (rotigotine) for treatment of early-stage Parkinson's disease is the generic firm's first attempt at the new drug market. The transdermal rotigotine patch is "the first submission of a novel new chemical entity from our…pipeline," the company says. Rotigotine is a non-ergot dopamine D2 agonist; Schwarz licensed the product from Aderis in 1998. Phase III studies in late-stage PD are ongoing, with an NDA projected for first-quarter 2006. A nasal spray rotigotine formulation is in Phase I studies for acute PD...
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.